HUTCHMED (NASDAQ:HCM) Shares Gap Up - Time to Buy?

Shares of HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report) gapped up before the market opened on Tuesday . The stock had previously closed at $13.89, but opened at $15.12. HUTCHMED shares last traded at $15.40, with a volume of 4,000 shares traded.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded shares of HUTCHMED from a "hold" rating to a "buy" rating in a research report on Friday, March 21st.

HUTCHMED Stock Up 12.5 %

The stock's 50-day simple moving average is $14.82 and its 200-day simple moving average is $15.89. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.81 and a quick ratio of 2.68.

Institutional Trading of HUTCHMED

Large investors have recently added to or reduced their stakes in the stock. Public Employees Retirement System of Ohio bought a new stake in HUTCHMED in the 3rd quarter valued at about $35,000. Barclays PLC grew its holdings in shares of HUTCHMED by 1,483.6% during the fourth quarter. Barclays PLC now owns 2,407 shares of the company's stock worth $35,000 after purchasing an additional 2,255 shares in the last quarter. Blue Trust Inc. raised its position in HUTCHMED by 99.9% during the fourth quarter. Blue Trust Inc. now owns 7,068 shares of the company's stock valued at $102,000 after purchasing an additional 3,532 shares in the last quarter. Summit Trail Advisors LLC grew its stake in shares of HUTCHMED by 14.4% during the fourth quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company's stock valued at $189,000 after buying an additional 1,647 shares during the last quarter. Finally, OLD Mission Capital LLC bought a new position in HUTCHMED during the 4th quarter valued at approximately $230,000. Hedge funds and other institutional investors own 8.82% of the company's stock.

About HUTCHMED

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.